Dominik Paul Modest

Summary

Affiliation: University of Munich
Country: Germany

Publications

  1. pmc Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group
    D P Modest
    Department of Medical Oncology and Comprehensive Cancer Center, University Hospital Grosshadern, Ludwig Maximilians Universitat, Munich German Cancer Consortium DKTK, German Cancer Research Centre DKFZ, Heidelberg
    Ann Oncol 27:1746-53. 2016
  2. pmc Left-sided primary tumors are associated with favorable prognosis in patients with KRAS codon 12/13 wild-type metastatic colorectal cancer treated with cetuximab plus chemotherapy: an analysis of the AIO KRK-0104 trial
    J C von Einem
    Department of Medicine III, University Hospital Grosshadern, University of Munich, Munich, Germany
    J Cancer Res Clin Oncol 140:1607-14. 2014
  3. doi request reprint [Chemotherapy of metastatic colorectal cancer]
    D P Modest
    Medizinische Klinik und Poliklinik III and Comprehensive Cancer Center, Klinikum der Universitat Munchen, Marchioninistr 15, 81377, Munchen, Deutschland
    Internist (Berl) 55:37-42. 2014
  4. pmc Effect of KRAS codon13 mutations in patients with advanced colorectal cancer (advanced CRC) under oxaliplatin containing chemotherapy. Results from a translational study of the AIO colorectal study group
    Anke Reinacher-Schick
    Department of Internal Medicine, Knappschaftskrankenhaus, Ruhr University Bochum, Bochum, Germany
    BMC Cancer 12:349. 2012
  5. doi request reprint KRAS allel-specific activity of sunitinib in an isogenic disease model of colorectal cancer
    D P Modest
    Department of Medicine III, University Hospital Grosshadern, University of Munich, Munich, Germany
    J Cancer Res Clin Oncol 139:953-61. 2013
  6. ncbi request reprint Impact of the specific mutation in KRAS codon 12 mutated tumors on treatment efficacy in patients with metastatic colorectal cancer receiving cetuximab-based first-line therapy: a pooled analysis of three trials
    Dominik P Modest
    Department of Medicine III, University Hospital Grosshadern, University of Munich, Munich, Germany
    Oncology 83:241-7. 2012
  7. doi request reprint Cetuximab-based or bevacizumab-based first-line treatment in patients with KRAS p.G13D-mutated metastatic colorectal cancer: a pooled analysis
    Dominik Paul Modest
    Department of Medicine III, Klinikum Grosshadern, University of Munich, Munich, Germany
    Anticancer Drugs 23:666-73. 2012
  8. doi request reprint The influence of KRAS and BRAF mutations on the efficacy of cetuximab-based first-line therapy of metastatic colorectal cancer: an analysis of the AIO KRK-0104-trial
    D P Modest
    Department of Medicine III, University of Munich, Munich, Germany
    Int J Cancer 131:980-6. 2012
  9. doi request reprint Prognostic value of cetuximab-related skin toxicity in metastatic colorectal cancer patients and its correlation with parameters of the epidermal growth factor receptor signal transduction pathway: results from a randomized trial of the GERMAN AIO CRC Stu
    Sebastian Stintzing
    Department of Haematology and Oncology, Comprehensive Cancer Center, Klinikum Grosshadern, University of Munich, Munich, Germany
    Int J Cancer 132:236-45. 2013
  10. doi request reprint Preoperative serum markers for individual patient prognosis in stage I-III colon cancer
    Clemens Giessen-Jung
    Department of Medical Oncology, Klinikum Grosshadern and Comprehensive Cancer Center, University of Munich, Marchioninistrasse 15, 81377, Munich, Germany
    Tumour Biol 36:7897-906. 2015

Collaborators

Detail Information

Publications23

  1. pmc Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group
    D P Modest
    Department of Medical Oncology and Comprehensive Cancer Center, University Hospital Grosshadern, Ludwig Maximilians Universitat, Munich German Cancer Consortium DKTK, German Cancer Research Centre DKFZ, Heidelberg
    Ann Oncol 27:1746-53. 2016
    ..To explore the impact of KRAS, NRAS and BRAF mutations as well as KRAS mutation variants in patients with metastatic colorectal cancer (mCRC) receiving first-line therapy...
  2. pmc Left-sided primary tumors are associated with favorable prognosis in patients with KRAS codon 12/13 wild-type metastatic colorectal cancer treated with cetuximab plus chemotherapy: an analysis of the AIO KRK-0104 trial
    J C von Einem
    Department of Medicine III, University Hospital Grosshadern, University of Munich, Munich, Germany
    J Cancer Res Clin Oncol 140:1607-14. 2014
    ..This analysis investigated the impact of primary tumor location on outcome of patients...
  3. doi request reprint [Chemotherapy of metastatic colorectal cancer]
    D P Modest
    Medizinische Klinik und Poliklinik III and Comprehensive Cancer Center, Klinikum der Universitat Munchen, Marchioninistr 15, 81377, Munchen, Deutschland
    Internist (Berl) 55:37-42. 2014
    ..The development of effective therapeutic strategies in patients with (K-)RAS mutant mCRC tumors must be promoted in the future and requires intensive research because the therapy options for this group of patients are very limited...
  4. pmc Effect of KRAS codon13 mutations in patients with advanced colorectal cancer (advanced CRC) under oxaliplatin containing chemotherapy. Results from a translational study of the AIO colorectal study group
    Anke Reinacher-Schick
    Department of Internal Medicine, Knappschaftskrankenhaus, Ruhr University Bochum, Bochum, Germany
    BMC Cancer 12:349. 2012
    ..To evaluate the value of KRAS codon 13 mutations in patients with advanced colorectal cancer (advanced CRC) treated with oxaliplatin and fluoropyrimidines...
  5. doi request reprint KRAS allel-specific activity of sunitinib in an isogenic disease model of colorectal cancer
    D P Modest
    Department of Medicine III, University Hospital Grosshadern, University of Munich, Munich, Germany
    J Cancer Res Clin Oncol 139:953-61. 2013
    ..To investigate the impact of different KRAS mutations on treatment with the tyrosine kinase inhibitor sunitinib in SW48 colorectal cancer cell line variants...
  6. ncbi request reprint Impact of the specific mutation in KRAS codon 12 mutated tumors on treatment efficacy in patients with metastatic colorectal cancer receiving cetuximab-based first-line therapy: a pooled analysis of three trials
    Dominik P Modest
    Department of Medicine III, University Hospital Grosshadern, University of Munich, Munich, Germany
    Oncology 83:241-7. 2012
    ..This study investigated the impact of specific mutations in codon 12 of the Kirsten-ras (KRAS) gene on treatment efficacy in patients with metastatic colorectal cancer (mCRC)...
  7. doi request reprint Cetuximab-based or bevacizumab-based first-line treatment in patients with KRAS p.G13D-mutated metastatic colorectal cancer: a pooled analysis
    Dominik Paul Modest
    Department of Medicine III, Klinikum Grosshadern, University of Munich, Munich, Germany
    Anticancer Drugs 23:666-73. 2012
    ..G13D mutant mCRC. The combination with capecitabine and irinotecan was associated with a more favourable outcome compared with infusional 5-FU and oxaliplatin...
  8. doi request reprint The influence of KRAS and BRAF mutations on the efficacy of cetuximab-based first-line therapy of metastatic colorectal cancer: an analysis of the AIO KRK-0104-trial
    D P Modest
    Department of Medicine III, University of Munich, Munich, Germany
    Int J Cancer 131:980-6. 2012
    ....
  9. doi request reprint Prognostic value of cetuximab-related skin toxicity in metastatic colorectal cancer patients and its correlation with parameters of the epidermal growth factor receptor signal transduction pathway: results from a randomized trial of the GERMAN AIO CRC Stu
    Sebastian Stintzing
    Department of Haematology and Oncology, Comprehensive Cancer Center, Klinikum Grosshadern, University of Munich, Munich, Germany
    Int J Cancer 132:236-45. 2013
    ..This effect of Cet-ST is independent of the KRAS mutation status, suggesting that Cet-ST rather relates to constitutional factors of the patient than alterations of the EGFR pathway in the tumour...
  10. doi request reprint Preoperative serum markers for individual patient prognosis in stage I-III colon cancer
    Clemens Giessen-Jung
    Department of Medical Oncology, Klinikum Grosshadern and Comprehensive Cancer Center, University of Munich, Marchioninistrasse 15, 81377, Munich, Germany
    Tumour Biol 36:7897-906. 2015
    ..The combined use of CEA together with CA 19-9 and γGT improve risk-adapted post-op surveillance...
  11. doi request reprint Analysis for prognostic factors of 60-day mortality: evaluation of an irinotecan-based phase III trial performed in the first-line treatment of metastatic colorectal cancer
    Clemens Giessen
    Department of Medical Oncology, Klinikum Grosshadern, University of Munich, Munich, Germany
    Clin Colorectal Cancer 10:317-24. 2011
    ..7% and 5.0%. This analysis aimed to evaluate clinical and histopathologic factors associated with 60-day mortality in first-line therapy for metastatic colorectal cancer (mCRC)...
  12. ncbi request reprint Cetuximab-based or bevacizumab-based first-line treatment in patients with KRAS p.G13D mutated metastatic colorectal cancer (mCRC)? A meta-analysis of 54 cases
    Volker Heinemann
    Department of Internal Medicine III, Klinikum Grosshadern, University of Munich, Munich, Germany Knappschaftskrankenhaus, Ruhr Universitat Bochum, Bochum, Germany Institut für Pathologie der Ruhr Universität Bochum an der Berufsgenossenschaftlichen Universitätsklinik Bergmannsheil GmbH, Bochum, Germany Institute for Medical Informatics, Biometry and Epidemiology, University of Munich, Munich, Germany Medical University of Vienna, Vienna, Austria CECOG, Central European Cooperative Oncology Group, Vienna, Austria University Hospital Zagreb Rebro, Zagreb, Croatia Department of Internal Medicine, Knappschaftskrankenhaus, Ruhr University Bochum, Bochum, Germany Comprehensive Cancer Center, Medical University Vienna, Vienna, Austria
    J Clin Oncol 30:511. 2012
    ..This analysis aims to answer the question whether first-line treatment of p.G13D mCRCs should contain cetuximab or bevacizumab...
  13. doi request reprint Progression-free survival as a surrogate endpoint for median overall survival in metastatic colorectal cancer: literature-based analysis from 50 randomized first-line trials
    Clemens Giessen
    Department of Medical Oncology, Klinikum Grosshadern and Comprehensive Cancer Center, Ludwig Maximilian University of Munich, Munich, Germany
    Clin Cancer Res 19:225-35. 2013
    ....
  14. ncbi request reprint Cetuximab-related skin toxicity in metastatic colorectal cancer (mCRC) patients and its correlation with molecular markers: Results from the German AIO CRC 0104 trial
    Sebastian Stintzing
    Department of Internal Medicine III, Klinikum Grosshadern, University of Munich, Munich, Germany Institute for Medical Informatics, Biometry and Epidemiology, University of Munich, Munich, Germany Department of Pathology, University of Munich, Munich, Germany Department of Dermatology and Allergology, University of Munich, Munich, Germany
    J Clin Oncol 30:491. 2012
    ..The role of cetuximab induced skin toxicity (Cet-ST), for the most acneiform skin rash, as a prognostic or a predictive factor of treatment efficacy is currently under discussion...
  15. doi request reprint Surrogate endpoints in second-line treatment for mCRC: a systematic literature-based analysis from 23 randomised trials
    Clemens Giessen
    Department of Medical Oncology, Klinikum Grosshadern and Comprehensive Cancer Center, University of Munich, Munich, Germany
    Acta Oncol 54:187-93. 2015
    ..To evaluate progression-free survival (PFS), overall response rate (ORR) and disease control rate (DCR) as potential surrogate endpoints (SEP) for overall survival (OS) in second-line treatment for metastatic colorectal cancer (mCRC)...
  16. pmc A randomized, phase III trial of capecitabine plus bevacizumab (Cape-Bev) versus capecitabine plus irinotecan plus bevacizumab (CAPIRI-Bev) in first-line treatment of metastatic colorectal cancer: the AIO KRK 0110 trial/ML22011 trial
    Clemens Giessen
    Department of Medical Oncology, Klinikum Grosshadern, University of Munich, Germany
    BMC Cancer 11:367. 2011
    ..The present study investigates the question whether this statement holds true also for bevacizumab-based first-line treatment including escalation- and de-escalation strategies...
  17. doi request reprint KRAS exon 2 mutations influence activity of regorafenib in an SW48-based disease model of colorectal cancer
    Peter Camaj
    Department of Surgery, University Hospital Grosshadern, University of Munich, Munich, Germany
    Future Oncol 11:1919-29. 2015
    ..To investigate the impact of KRAS mutation variants on the activity of regorafenib in SW48 colorectal cancer cells...
  18. doi request reprint Evaluation of preoperative serum markers for individual patient prognosis in stage I-III rectal cancer
    Clemens Giessen
    Department of Medical Oncology, Klinikum Grosshadern and Comprehensive Cancer Center, University of Munich, Marchioninistrasse 15, 81377, Munich, Germany
    Tumour Biol 35:10237-48. 2014
    ..In addition to tumor baseline parameters, routine analysis of SAA together with CEA provided markedly improved prognostic value on CSS and DFS in resected rectal cancer...
  19. doi request reprint The relevance of primary tumour location in patients with metastatic colorectal cancer: A meta-analysis of first-line clinical trials
    Julian Walter Holch
    Department of Medical Oncology, University Hospital Grosshadern, Ludwig Maximilians Universitat Munchen, Marchioninistrasse 15, 81377 Munich, Germany Comprehensive Cancer Center, University Hospital Grosshadern, Ludwig Maximilians Universitat Munchen, Marchioninistrasse 15, 81377 Munich, Germany Electronic address
    Eur J Cancer 70:87-98. 2017
    ..Retrospective subgroup analyses suggest that primary tumour location (PTL) has a prognostic importance and relates to response to targeted therapy...
  20. ncbi request reprint Evaluating the agreement between the empirical volumes of tumor lesions and the estimated volumes of tumor lesions based on the longest diameter
    Ruediger P Laubender
    Institute for Medical Informatics, Biometry and Epidemiology, University of Munich, Munich, Germany Merck KGaA, Darmstadt, Germany Department of Internal Medicine III, Klinikum Grosshadern, University of Munich, Munich, Germany Department of Clinical Radiology, Klinikum Grosshadern, University of Munich, Munich, Germany
    J Clin Oncol 30:635. 2012
    ..However, volume measurements might reflect the clinical impact of the disease process more precisely. Therefore, we investigated if the volume of a tumor lesion can be reconstructed from RECIST- or WHO-based measurements...
  21. doi request reprint NeoFLOT: Multicenter phase II study of perioperative chemotherapy in resectable adenocarcinoma of the gastroesophageal junction or gastric adenocarcinoma-Very good response predominantly in patients with intestinal type tumors
    Christoph Schulz
    Department of Medical Oncology, Klinikum Grosshadern and Comprehensive Cancer Center, University of Munich, Munich, Germany
    Int J Cancer 137:678-85. 2015
    ..Very good response (pCR and <10% residual tumor) was predominantly observed in patients with intestinal type tumors. ..
  22. doi request reprint Isolated pulmonary metastases define a favorable subgroup in metastatic pancreatic cancer
    Stephan Krüger
    Department of Internal Medicine III and Comprehensive Cancer Center, Klinikum Grosshadern, Ludwig Maximilians University of Munich, D 81377 Munich, Germany
    Pancreatology 16:593-8. 2016
    ..Pulmonary metastasis as first site of dissemination in PC is a rare event and might define a biologically distinct subgroup in metastatic PC...
  23. doi request reprint [Use of tumor markers as screening tools - sense or nonsense?]
    Dominik Paul Modest
    Medizinische Klinik und Poliklinik III, Klinikum der Universitat Munchen, Munchen, Deutschland
    Dtsch Med Wochenschr 140:1438-41. 2015
    ..Tumor markers may already be used in some follow-up care settings to detect recurrences at an early stage...